(Reuters) -Edwards Lifesciences raised its 2025 sales forecast on Thursday, citing strong demand for its artificial heart valves and other medical devices, after posting better-than-expected results for the second quarter.
Shares of the California-based company rose about 8% in extended trading.
Investor confidence in medical device makers has climbed in recent quarters, underpinned by robust demand for surgical procedures, particularly among older adults.
Edwards now expects full-year sales in the range of $5.9 billion to $6.1 billion, having raised the lower end of its previous forecast from $5.7 billion while maintaining the upper end.
Earlier on Thursday, larger rival Boston Scientific also raised its annual profit forecast, buoyed by strong demand for its heart devices.
Sales of Edwards’ flagship transcatheter aortic valve replacement (TAVR) devices, used in minimally invasive heart surgeries, jumped 8.9% to $1.13 billion in the quarter ended June 30, topping analysts’ average estimate of $1.09 billion, according to data compiled by LSEG.
On an adjusted basis, Edwards earned 67 cents per share in the second quarter, beating Wall Street’s estimate of 62 cents per share.
It reported revenue of $1.53 billion, surpassing market expectation of $1.49 billion.
The company said it now expects its 2025 adjusted earnings to come in at the high end of its earlier forecast range of $2.40 to $2.50 per share.
Edwards said its forecast factors in current tariffs and warned that any changes or new tariffs could significantly impact future results.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Alan Barona)
Comments